BioTuesdays

Tag - hCDR1

XTL hopes to begin major lupus trial next year

By Len Zehr XTL Biopharmaceuticals (NASDAQ:XTLB; TASE:XTL) is aiming to begin a Phase 2b clinical trial in the first half of 2015 with its hCDR1 peptide to treat patients with systemic lupus erythematosus (SLE). “We are...